Clinical Trial

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Trial Details
NCT Number NCT07492927
Lead Sponsor Xijing Hospital
Collaborators: Shaanxi Provincial People's Hospital, Weinan Central Hospital, Shaanxi University of Chinese Medicine, LanZhou University, Qinghai University, Ningxia Medical University, Northwestern University, Yan'an University Affiliated Hospital, Air Force Military Medical University, China
Conditions Clinically Significant Prostate Cancer
Enrollment 1,700 participants
Start Date 2021-03-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-25